- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07246291
Estudo Comparativo da EnliTuo® Antes e Depois da Alteração Tecnológica em Voluntários Masculinos Saudáveis
Estudo Comparativo Randomizado, Duplamente Cego, Controlado Paralelo, de Dose Única, Farmacocinético, de Segurança e Imunogenicidade do EnliTuo® Antes e Após a Mudança Tecnológica em Voluntários Masculinos Saudáveis
This study is a randomized, double-Blind, parallel-controlled, single-dose pharmacokinetic, safety, and immunogenicity comparative study of EnliTuo® before and after technology change in healthy male volunteers.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Shanghai, China
- Shanghai Xuhui Central Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Healthy males aged ≥ 18 years and ≤ 45 years on the day of signing the informed consent form;
- At screening, body weight ≥ 50 kg and ≤ 80 kg, with a Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive of boundary values);
- Capable of understanding the study, including its purpose, research procedures, potential risks, etc., and able to communicate well with researchers and complete the study in accordance with the study requirements;
- Voluntarily sign the informed consent form.
Exclusion Criteria:
- Subjects with any abnormally clinically significant findings in comprehensive examinations (vital signs, physical examination, electrocardiogram, chest X-ray, abdominal ultrasound, blood routine, urine routine, blood biochemistry, coagulation, etc.) as judged by the investigator;
- Subjects with a history of major diseases in the cardiovascular, endocrine, nervous, digestive, respiratory, genitourinary, hematological, immune, or mental systems, or currently suffering from any disease in the above systems;
- Subjects with a known or suspected history of keratitis, ulcerative keratitis, conjunctivitis, blepharitis, or severe dry eye;
- Subjects with hereditary bleeding tendency, coagulation dysfunction, or a history of thrombotic or hemorrhagic diseases;
- Subjects with active infections requiring systemic treatment;
- Subjects positive for any of HBV surface antigen, HCV antibody, HIV antibody, or Treponema pallidum antibody;
- Subjects with a history of malignant tumors within the past 5 years, except for completely resected in-situ cutaneous basal cell carcinoma or squamous cell carcinoma;
- Subjects who have undergone surgical operations within 4 weeks before screening, or plan to undergo surgery during the trial period;
- Subjects who have used any prescription drugs, over-the-counter drugs, traditional Chinese medicines, proprietary Chinese medicines, health supplements, etc., within 4 weeks before screening, or whose use of the above substances has not exceeded 5 half-lives (whichever is longer);
- Subjects who have used any biological products or received any vaccines within 12 weeks before screening, or plan to receive any vaccines during the study period;
- Subjects currently enrolled in other clinical studies of drugs or medical devices, or whose time since the end of the last enrolled clinical study is less than 12 weeks, or whose time since the last trial drug administration has not exceeded 5 half-lives (whichever is longer);
- Subjects positive for anti-drug antibodies against anti-epidermal growth factor receptor antibodies;
- Subjects with substance abuse, or who have used soft drugs within 3 months before screening or hard drugs within 1 year before screening; or who consume excessive tea, coffee, and/or caffeinated beverages daily (more than 8 cups, 1 cup = 250 mL); or who have a positive urine drug screen;
- Subjects with alcoholism, or whose weekly alcohol consumption exceeds 14 units within 3 months before screening (1 unit = 17.7 mL ethanol, i.e., 1 unit = 357 mL of beer with 5% alcohol content, 43 mL of liquor with 40% alcohol content, or 147 mL of wine with 12% alcohol content); or who have a positive alcohol breath test; and those who cannot cooperate with alcohol prohibition during the study;
- Subjects who smoked more than 10 cigarettes per day on average within 6 months before screening;
- Subjects who engaged in strenuous activities within 72 hours before drug administration, or cannot avoid strenuous activities during the study; or have other physiological or pathological conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug;
- Subjects who have donated blood (including component blood) or lost more than 400 mL of blood, or received blood transfusions within 3 months before screening; or donated blood (including component blood) or lost more than 200 mL of blood within 1 month before screening;
- Subjects with a known history of allergy to the active ingredient or any excipient of the study drug, or to other biological products; or with a history of atopic allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.); or with allergic diathesis;
- Subjects who cannot tolerate venipuncture or have a history of fainting due to needle or blood;
- Subjects with special dietary requirements who cannot accept the diet provided by the clinical trial center;
- Subjects who cannot take effective contraceptive measures or plan to donate sperm within 3 months after the administration of the study drug;
- Other conditions deemed by the investigator to make the subject unsuitable for participating in this study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: New technology Enlituo
treated with new technology Enlituo through single intravenous drip |
250 mg/m^2, single intravenous drip |
|
Comparador Ativo: Approved technology Enlituo
treated with Approved technology Enlituo through single intravenous drip |
250 mg/m^2, single intravenous drip |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
AUC0-∞
Prazo: From enrollment to the end of treatment at 28 days
|
Area under the concentration time curve extrapolated to infinity |
From enrollment to the end of treatment at 28 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
AUC0-t
Prazo: From enrollment to the end of treatment at 28 days
|
Area under the concentration time curve from time zero to the last measurable time point. |
From enrollment to the end of treatment at 28 days
|
|
Cmax
Prazo: From enrollment to the end of treatment at 28 days
|
Peak concentration. |
From enrollment to the end of treatment at 28 days
|
|
Tmax
Prazo: From enrollment to the end of treatment at 28 days
|
time to peak |
From enrollment to the end of treatment at 28 days
|
|
t1/2
Prazo: From enrollment to the end of treatment at 28 days
|
half-life |
From enrollment to the end of treatment at 28 days
|
|
λz
Prazo: From enrollment to the end of treatment at 28 days
|
Terminal Elimination Rate Constant |
From enrollment to the end of treatment at 28 days
|
|
CL
Prazo: From enrollment to the end of treatment at 28 days
|
clearance |
From enrollment to the end of treatment at 28 days
|
|
Vd
Prazo: From enrollment to the end of treatment at 28 days
|
volume of distribution |
From enrollment to the end of treatment at 28 days
|
|
Immunogenicity
Prazo: From enrollment to the end of treatment at 28 days
|
Anti-drug antibody positive rate |
From enrollment to the end of treatment at 28 days
|
|
Adverse Event
Prazo: From enrollment to the end of treatment at 6 months
|
Incidence and Severity of Adverse Events |
From enrollment to the end of treatment at 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jingying Jia, PhD, Xuhui Central Hospital, Shanghai
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- CMAB009-C-102
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
After the study result is published, email the application registration contact or the study leader to obtain it.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .